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Introduction
Superparamagnetic iron oxide nanoparticle (SPIO)-based
molecular imaging agents targeting macrophages have
been developed and successfully applied in animal mod-
els of myocardial infarction.
Purpose
The purpose of this clinical trial was to investigate
whether molecular magnetic resonance imaging (MRI)
of macrophages using ferucarbotran (Resovist®) allows
improved visualization of the myocardial (peri-)infarct
zone compared to conventional gadolinium-based
necrosis/fibrosis imaging in patients with acute myocar-
dial infarction.
Methods
The clinical study NIMINI-1 was performed as a pro-
spective, non-randomised, non-blinded, single agent
phase III clinical trial. Twenty patients who had experi-
enced either an acute ST-elevation or non-ST-elevation
myocardial infarction (STEMI/NSTEMI) were included
to this study. Following coronary angiography, a first
baseline cardiovascular magnetic resonance (CMR)
study (pre-SPIO) was performed within seven days after
onset of cardiac symptoms. A second CMR study (post-
SPIO) was performed either 10min, 4h, 24h or 48h after
ferucarbotran administration. The CMR studies com-
prised cine-CMR, T2-weighted “edema” imaging,
T2*-weighted cardiac imaging and T1-weighted late-
gadolinium-enhancement (LGE) imaging.
Results
The median extent of short-axis in-plane LGE was 28%
(IQR 19-31%). Following Resovist® administration the
median extent of short-axis in-plane T2*-weighted
hypoenhancement (suggestive of intramyocardial hemor-
rhage and/or SPIO accumulation) was 0% (IQR 0-9%;
p=0.68 compared to pre-SPIO). A significant in-slice
increase (>3%) in the extent of T2*-weighted “hypoen-
hancement” (post-SPIO compared to pre-SPIO) was
seen in 6/16 patients (38%). However, no patient
demonstrated “hypoenhancement” in T2*-weighted
images following Resovist® administration that exceeded
the area of LGE.
Conclusions
T2/T2*-weighted MRI aiming at non-invasive myocar-
dial macrophage imaging using the approved dose of
ferucarbotran does not allow improved visualization of
the myocardial (peri-) infarct zone compared to conven-
tional gadolinium-based necrosis/fibrosis imaging.
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